We could not find any results for:
Make sure your spelling is correct or try broadening your search.
UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Five Prime Therapeutics, Inc. (FPRX) has been in the news over the past few days. Investors at Five Prime, which went public in September last year, had plenty to cheer when the company inked a...
UCB (UCBJF) recently presented data from a study showing the effect of Neupro on cardiovascular measures in patients with restless legs syndrome (RLS). The double-blind, placebo-controlled...
Nektar Therapeutics (NKTR) reported a loss of 48 cents per share in the first quarter of 2013, wider than the year-ago loss of 34 cents and the Zacks Consensus Estimate of a loss of 41 cents...
Questcor Pharmaceuticals Inc. (QCOR) reported first quarter 2013 adjusted earnings per share of 67 cents, up 15.5% from the year-ago period. Earnings were, however, well below the Zacks...
Valeant Pharmaceuticals’ (VRX) first quarter 2013 earnings of $1.27 (excluding special items but including stock-based compensation expense) were short of the Zacks Consensus Estimate by a...
Shire’s (SHPG) first quarter 2013 earnings (excluding special items) of 1.63 as per American Depositary Share (ADS) beats the Zacks Consensus Estimate of $1.61. The reported...
Recently, GlaxoSmithKline (GSK) announced that the US Food and Drug Administration (FDA) has extended the review period for Glaxo’s oncology candidate, trametinib, by three months. A final...
ViroPharma Inc.’s ( VPHM ) first quarter 2013 adjusted loss (excluding special items but including stock-based compensation) came in at 7 cents per share compared to year-ago earnings...
Actavis, Inc.’s (ACT) first quarter 2013 earnings of $1.99 per share beat the Zacks Consensus Estimate of $1.87 and increased 21% from the year-ago earnings. Revenues for the reported...
Momenta Pharmaceuticals Inc. (MNTA) reported first quarter 2013 net loss per share of 48 cents, wider than the Zacks Consensus Estimate of a loss of 43 cents and the year-ago loss of 10...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.6441 | 0.829201866095 | 198.275 | 199.9191 | 198.275 | 80 | 198.275 | CS |
4 | 4.0441 | 2.0646330568 | 195.875 | 199.9191 | 195.875 | 56 | 197.01139053 | CS |
12 | 15.9191 | 8.65168478261 | 184 | 199.9191 | 174 | 309 | 187.28624306 | CS |
26 | 50.0391 | 33.3861088871 | 149.88 | 199.9191 | 149.85 | 231 | 178.70034495 | CS |
52 | 112.8191 | 129.528243398 | 87.1 | 199.9191 | 87.1 | 290 | 142.70207939 | CS |
156 | 87.3691 | 77.6269213683 | 112.55 | 199.9191 | 68.301062 | 675 | 93.63875022 | CS |
260 | 118.5191 | 145.600859951 | 81.4 | 199.9191 | 67.39 | 1078 | 92.37454781 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions